US Patent No: 7,125,689

Number of patents in Portfolio can not be more than 2000

Method for rendering streptokinase less immunogenic to a human

ALSO PUBLISHED AS: 20030153043

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Protein, or parts of proteins, may be rendered non-immunogenic, or less immunogenic, to a given species by identifying in their amino acid sequences one or more potential epitopes for T-cells of the given species and modifying the amino acid sequence to eliminate at least one of the T-cell epitopes. This eliminates or reduces the immunogenicity of the protein when exposed to the immune system of the given species. Monoclonal antibodies and other immunoglobulin-like molecules can particularly benefit from being de-immunised in this way: for example, mouse-derived immunoglobulins can be de-immunised for human therapeutic use.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
MERCK PATENT GMBHDARMSTADT2833

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Adair, Fiona Suzanne Aberdeen, GB 5 10
Carr, Francis Joseph Balmedie, GB 32 111
Carter, Graham By Newmachar, GB 35 87
Hamilton, Anita Anne Aberdeen, GB 5 10

Cited Art Landscape

Patent Info (Count) # Cites Year
 
CENTRO DE INMUNOLOGIA MOLECULAR (1)
5,712,120 Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them 40 1995

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
PRECISION BIOLOGICS, INC. (5)
7,314,622 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers 4 2006
7,829,678 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers 2 2008
8,535,667 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers 0 2010
8,524,456 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers 0 2010
8,802,090 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers 0 2011
 
NEOGENIX ONCOLOGY, INC. (1)
7,763,720 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers 1 2007

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 24, 2014
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 24, 2018
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00